Egis Gyógyszergyár

What Egis Gyógyszergyár does

Egis Gyógyszergyár Zrt. is a Hungary-based generic pharmaceutical company operating as a wholly-owned subsidiary of the French Servier Group, a non-profit foundation-governed international pharmaceutical organization. Founded in 1912 by pharmacist Dr. Sándor Balla in Budapest, the company has developed over 112 years into one of the leading branded generic pharmaceutical manufacturers in Central Eastern Europe, with a therapeutic focus on cardiovascular and central nervous system diseases, alongside oncology, diabetology, dermatology, anticoagulation, and women's health.

The company operates a vertically integrated value chain spanning R&D, active pharmaceutical ingredient (API) manufacturing, finished product manufacturing (tablets, injections, galenic formulations), high-speed packaging, and sales. Manufacturing is concentrated at two Hungarian sites: the Budapest headquarters (API and finished product plants, including a new HUF 30 billion API plant inaugurated in 2025) and the Körmend facility (galenic, packaging, and specialty oncology manufacturing). The technology base emphasizes high-potency drug substance manufacturing, EU serialization compliance since 2019, and oncology-specialized production. R&D investment was EUR 56.6 million in 2024/2025, focused on value-added branded generics and oncological active ingredient development in collaboration with HUN-REN Research Centre.

Egis monetizes through four revenue streams: sale of finished pharmaceutical products (prescription and OTC), API sales to pharmaceutical partners, contract development and manufacturing services (Egis Pharma Services, launched 2023), and licensing royalties in non-strategic markets. The go-to-market model relies on 17 wholly-owned subsidiaries and representative offices covering CEE, Russia, and CIS countries, supplemented by licensing partnerships in additional markets. The company reported EUR 773.3 million in net sales for the 2024/2025 financial year, treats approximately 30 million patients, and holds a Top 3 supplier position in Hungary by boxes sold.

Name

Egis Gyógyszergyár

Legal name

Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság

Website

https://int.egis.health

Company type

Private

Founded year

1912

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Egis Gyógyszergyár is a Hungary-headquartered generic pharmaceutical manufacturer (Servier Group subsidiary) producing branded generics in cardiovascular, CNS, oncology, and dermatology for distribution across 17 directly operated countries and 100+ partner markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Cardiovascular medicines
• Central nervous system drugs
• Contract manufacturing

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Finished pharmaceutical products: Sale of prescription and OTC pharmaceutical products including tablets, injections, ointments, suppositories, solutions, and syrups. Portfolio of 656 products across 177 product lines containing 163 active ingredients.
2. Active pharmaceutical ingredients (API): Manufacturing and sale of active pharmaceutical ingredients to pharmaceutical partners. From 2023, contract development and manufacturing services offered to pharmaceutical partners.
3. Licensing royalties: Licensing-out activities for marketing products in non-strategic markets through local pharmaceutical companies
4. Contract manufacturing services: Small molecule drug substance and intermediate development and manufacturing services offered to pharmaceutical partners since 2023

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Egis Gyógyszergyár is a generic pharmaceutical manufacturer that develops, produces, and sells prescription and over-the-counter medicines, with primary therapeutic focus on cardiovascular and central nervous system diseases. The company operates a vertically integrated value chain spanning R&D, active pharmaceutical ingredient (API) manufacturing, finished dosage form production, packaging, and sales. Products are distributed through wholly-owned subsidiaries in 17 countries, licensing partners, and contract manufacturing services.

Product overview

Egis Gyógyszergyár is a Hungarian generic pharmaceutical company offering a comprehensive portfolio of prescription and over-the-counter (OTC) products. The company manufactures active pharmaceutical ingredients (APIs) and finished products in various forms including tablets, injections, and galenic formulations (ointments, suppositories, solutions, syrups). Key therapeutic areas include cardiovascular diseases, central nervous system disorders, diabetology, anticoagulation, iron deficiency, uric acid reduction, allergic diseases, dermatology and wound care. OTC products include Reparon (haemorrhoid treatment), Betadine (antiseptic), Cralex (diarrhoea treatment), and Telviran (herpes treatment). The company also offers contract development and manufacturing services (Egis Pharma Services) for pharmaceutical partners. Products are available in 100+ countries through subsidiaries in 17 countries and distribution partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription Pharmaceutical Products Branded generic prescription medicines covering cardiovascular diseases, central nervous system disorders, diabetology, anticoagulation, oncology, and additional therapeutic areas, manufactured as tablets, injections, ointments, suppositories, solutions, and syrups and sold to pharmacies, wholesalers, and healthcare providers.
• OTC Product Portfolio Over-the-counter medicines sold without prescription for minor ailments including haemorrhoids (Reparon), skin disinfection (Betadine), diarrhoea (Cralex), and herpes (Telviran). Targeted at consumers seeking self-medication for minor health conditions.
• Reparon Over-the-counter haemorrhoid treatment ointment for treating haemorrhoids. Targeted at adult consumers seeking self-medication.
• Betadine Antiseptic solution used to kill pathogens on the skin for disinfection. Targeted at consumers and healthcare providers seeking antiseptic skin treatment.
• Cralex Coal-based over-the-counter medicine for treating diarrhoea. Targeted at consumers seeking self-medication for digestive ailments.
• Telviran Over-the-counter topical treatment for herpes outbreaks. Targeted at consumers seeking self-medication for cold sores and herpes symptoms.
• Active Pharmaceutical Ingredients (API) Active pharmaceutical ingredients manufactured and sold to pharmaceutical partners. High-potency API manufacturing capabilities at Budapest site and dedicated API production capacity.
• Egis Pharma Services - Contract Development Contract development services for small molecule drug substances and intermediates offered to pharmaceutical partners. Targeted at pharmaceutical companies seeking specialized API development capabilities.
• Egis Pharma Services - Contract Manufacturing Contract manufacturing services for small molecule drug substances and intermediates offered to pharmaceutical partners. Targeted at pharmaceutical companies seeking EU-based cGMP-compliant manufacturing capacity.
• Licensing-out Activities Licensing arrangements with local pharmaceutical companies in non-strategic markets where Egis does not have direct presence. Targeted at pharmaceutical companies seeking differentiated products for local distribution.

Quantifiable outcome

• Products reach 105 countries and treat approximately 30 million patients
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Budapest University of Economics (BME) - Faculty of Mechanical EngineeringminorStrategic or Co-development Partner · 1 September 2025Cooperation agreement following collaboration with Faculty of Chemical Technology and Biotechnology. Aims to support students' practical training, enhance competency development, and showcase pharmaceutical industry opportunities to young professionals.
• University of SzegedcoreStrategic or Co-development Partner · 5 March 2025Established SZTE-Egis Industrial Partnership Department at Faculty of Pharmacy. Launched 'Egis Pharma A-Z' credit-point course at university. Supporting students' practical training and talent development.
• HUN-REN Research Centre for Natural Sciences (TTK)coreStrategic or Co-development Partner · 31 December 2024Oncological active ingredient and preparation development collaboration from 2021-2024. Worked on development of 14 active ingredients and 5 preparations in the project titled 'Development of innovative, high added value oncological drug preparations for personalized therapies.'
• Servier GroupcoreOthersEgis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with headquarters in France. Servier Group operates the career site and provides global standards and frameworks.
• Teva Pharmaceutical Industries Ltd.minorChannel Partner/ Reseller/ DistributorEgis acquired a well-known Hungarian dermatological product line from Teva Pharmaceutical Industries Ltd., backed by Hungarian Competition Authority certification, to strengthen position in Hungarian OTC market.
• Jadran-Galenski Laboratorij (JGL)minorChannel Partner/ Reseller/ DistributorEgis acquired D-Panthenol and women's health product portfolio from JGL to strengthen presence in major export markets including Russia.

Scale indicators10 records

Recent moves12 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/shareArticle?mini=true&url=https://int.egis.health/a/capacity-expansion-investments-are-ongoing-in-kormend&title=Egis+%7C+Capacity+expansion+investments+are+ongoing+in+K%C3%B6rmend

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egis Gyógyszergyár